Dexmedetomidine as Adjunctive Therapy for the Treatment of Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis

• Published in: Pharmaceuticals (Basel, Switzerland) Switzerland), 2024-09, Vol.17 (9), p.1125
• Main Authors: Fiore, Marco, Alfieri, Aniello, Torretta, Giacomo, Passavanti, Maria Beatrice, Sansone, Pasquale, Pota, Vincenzo, Simeon, Vittorio, Chiodini, Paolo, Corrente, Antonio, Pace, Maria Caterina
• Format: Article
• Language: English
• Subjects: Alcohol withdrawal; alcohol withdrawal syndrome; Alcoholism; Anesthesia; Benzodiazepines; Cardiac arrhythmia; Care and treatment; Citation management software; Dexmedetomidine; Diagnosis; Dosage and administration; Drinking of alcoholic beverages; Drug therapy; Drug withdrawal symptoms; Health care expenditures; Hospital costs; Hypotension; intensive care; Intubation; Meta-analysis; Patient outcomes; sedatives; Substance abuse; Systematic Review; Testing; Tremor
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph17091125

Alcohol withdrawal syndrome (AWS) is defined as the cessation or reduction in heavy and prolonged alcohol use within several hours to a few days of cessation. The recommended first-line therapy for AWS ranging from mild to severe or complicated remains benzodiazepines; in cases where benzodiazepines are not adequate in controlling persistent autonomic hyperactivity or anxiety, dexmedetomidine could be utilized. The possible advantage of dexmedetomidine compared to benzodiazepines is that it does not cause respiratory depression, thus reducing the risk of intubation and hospitalization in the ICUs, with the potential reduction in healthcare costs. The purpose of this systematic review and meta-analysis (PROSPERO CRD42018084370) is to evaluate the effectiveness and safety of dexmedetomidine as adjunctive therapy to the standard of care for the treatment of AWS. We retrieved literature from PubMed, EMBASE, and CENTRAL until 10 January 2024. Eligible studies were both randomized trials and nonrandomised studies with a control group, published in the English language and peer-reviewed journals. The primary outcome was tracheal intubation; secondary outcomes were (i) bradycardia and (ii) hypotension. A total of 3585 papers were retrieved: 2635 from EMBASE, 930 from Medline, and 20 from CENTRAL. After eliminating duplicates, 2960 papers were screened by title and abstract; 75 out of the 2960 papers were read in full text. The qualitative synthesis included nine of all manuscripts read in full text. The quantitative synthesis included eight studies for the primary outcome (tracheal intubation), seven for the secondary outcome bradycardia, and six for the secondary outcome hypotension. The meta-analysis showed that Dexmedetomidine, as adjunctive therapy, is not more effective than standard therapy in reducing the risk of tracheal intubation in AWS [RR: 0.57, 95% CI: 0.25-1.3, = 0.15]. It also appears to be less safe than sedative therapy as it significantly increases the risk of bradycardia [RR: 2.68, 95% CI: 1.79-4.16, = 0.0016]. Hypotension was not significantly different in patients who received dexmedetomidine [RR: 1.5, 95% CI: 0.69-3.49, = 0.21].